Hematologic Oncology

In this podcast interview, Dr. William Wierda discusses the role of venetoclax in treating patients with chronic lymphocytic leukemia, particularly in light of recent trial results.

The FDA has expanded the approval of vemurafenib (Zelboraf) to include the treatment of Erdheim–Chester disease in adult BRAF V600–positive patients. This marks the first approval from the agency for treating this rare blood cancer.

The BCL-2 inhibitor venetoclax had an acceptable safety profile and showed evidence of activity in patients with relapsed/refractory multiple myeloma.

In patients with chronic myeloid leukemia treated with bosutinib who were resistant or intolerant to previous tyrosine kinase inhibitors, health-related quality of life was well maintained over the long term.

A team of investigators from multiple institutions has proposed new guidelines for monitoring, grading, and managing the side effects of CAR T-cell therapy.

A team of investigators from multiple institutions has proposed new guidelines for monitoring, grading, and managing the side effects of CAR T-cell therapy.

Researchers have discovered that genetic mutations associated with Fanconi Anemia may also result in a higher risk for certain cancers, even in patients who don't exhibit symptoms of the disease.

In this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.

Researchers have developed a model that has prognostic value in predicting favorable or unfavorable responses to immunomodulatory derivatives in patients with multiple myeloma.

Characteristics of the diabetic intrauterine environment may promote the development of acute lymphoblastic leukemia in offspring, according to the results of a new study.

A study by German investigators is elucidating the role of tyrosine kinase inhibitors in targeting FLT3 in acute myeloid leukemia.

About one in every 25 patients with chronic lymphocytic leukemia had abnormal liver function tests, and one in four developed liver dysfunction within 10 years, according to the results of a retrospective study.

Survival of patients with myelofibrosis who undergo splenectomy is adversely affected by older age, the need for transfusion, and leukocyte and circulating blast cell counts, according to a new analysis.

Non-Hodgkin lymphoma patients who have preexisting cardiovascular risk factors are at an increased risk of heart failure and are often prescribed anthracyclines less frequently, according to a large population-based study.

The phase III ALCYONE study showed that daratumumab in combination with bortezomib, melphalan, and prednisone is a viable front-line option for myeloma patients who are not candidates for ASCT.

The FDA has released a statement regarding safety concerns that led to a clinical hold on three trials of pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma, and the active role of the FDA in protecting patient safety.

Researchers at St. Jude Children’s Research Hospital have discovered a vulnerability that may easily translate into new targeted drug therapies that block heme biosynthesis, killing leukemic cells.

This video highlights patient variables, including kidney function or history of diabetes, that can help guide treatment in chronic myeloid leukemia.

In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.

Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.

Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Patients with newly diagnosed multiple myeloma treated with lenalidomide maintenance therapy after undergoing autologous stem-cell transplantation had significantly improved overall survival compared with observation or placebo.

Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States.

A new study indicates that patients with primary immunodeficiency diseases may be at a much higher risk for certain cancers, especially lymphoma.

This video highlights novel approaches using immunotherapies and vaccines for advancing treatment in multiple myeloma.

Arsenic trioxide consolidation was well tolerated in pediatric patients with acute promyelocytic leukemia and allowed for significant reductions in cumulative anthracycline doses.

Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study.

In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.

The US Food and Drug Administration has approved the tyrosine kinase inhibitor ibrutinib (Imbruvica) for adult patients with chronic graft vs host disease who have failed on one or more lines of prior systemic therapy.